Complement Factor H and D Assay for Ischemic Heart Disease Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing ischemic heart disease lack a convenient and highly accurate biomarker for detecting the presence and severity of the condition, with existing biomarkers either being unsuitable for human application or requiring complex operations.
Innovation Solution
The use of complement factor H and/or complement factor D in blood samples as biomarkers, where their concentrations are assayed and compared to reference values to determine the presence and severity of ischemic heart disease, utilizing techniques such as immunoassay or mass spectrometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If CRP level is used as a biomarker for ischemic heart disease, then the biomarker can be measured in blood samples, but the CRP level alone cannot serve as an accurate index for disease risk
Solution Approach 1:
The patent combines multiple biomarkers (complement factor H and complement factor D) into a single diagnostic system. By measuring both factors together and comparing their ratio or combined levels against reference values, the system achieves higher diagnostic accuracy than using CRP alone, while maintaining the convenience of blood sample analysis.
2Measurement precision
If complement factor H or D is assayed in blood samples, then accurate evaluation of ischemic heart disease can be achieved, but the assay methods require specialized techniques such as immunoassay or mass spectrometry
Solution Approach 1:
The patent employs immunoassay methods that can detect multiple complement factors (H and D) using standardized reagents and procedures. This multi-functional approach allows accurate measurement of different biomarkers through a single versatile technique, reducing the need for multiple specialized methods while maintaining high diagnostic precision.
3Adaptability or versatility
If previous biomarker methods from mouse models are applied to humans, then research findings can be translated, but it is uncertain whether these biomarkers can be applied to human examination
Solution Approach 1:
The patent transitions from mouse model biomarkers to human-applicable biomarkers by selecting complement factors H and D that are conserved across species but can be reliably measured in human blood. The assay conditions, reference ranges, and interpretation criteria are specifically optimized for human samples, ensuring both adaptability from research models and reliability in clinical human examination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and convenient evaluation of ischemic heart disease, allowing for early detection and progression assessment, facilitating timely treatment and improving diagnostic efficiency.
Implementation Method 1
assaying complement factor H and/or complement factor D in a sample
Data Source
AI summary
It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.